Nothing is possible without the synergy of partners working toward a common goal: improving patient care.

Here are the major partners that have made it possible to establish the Chair on multiple myeloma.

Myeloma Canada

One of the challenges facing the myeloma patient community is the general lack of awareness of this relatively rare cancer. Consequently, many patients are not well-informed about the resources that are available to them and often feel alone in their battle. To address this concern, Myeloma Canada, a non-profit entity with charitable organization status, was created in 2005 by and for people living with multiple myeloma.

Myeloma Canada is the creator of the Chair on multiple myeloma.

To learn more:

Université de Montréal

Université de Montréal was founded in 1878, and with over 60,000 students (including its affiliates École Polytechnique and HEC Montréal), it is the largest university in Quebec and the third largest in Canada. The university is considered to be one of the most cosmopolitan institutions in the country, as over 7,000 of its students come from abroad. Université de Montréal awards over 11,000 qualifications every year. Deeply rooted in Montreal and dedicated to its international mission, Université de Montréal is one of the greatest universities in the French-speaking world.

To learn more:

The HMR Foundation

As one of its key partners, the HMR Foundation supports Hôpital Maisonneuve-Rosemont, a centre affiliated with the Université de Montréal, in its strategic development orientations in order to respond more effectively to patient needs. Every year, thanks to fundraising campaigns and original fund development activities, the HMR Foundation raises over 10 million dollars that it dedicates entirely to structuring projects. In collaboration with partners, donors and private and corporate foundations, the HMR Foundation makes a positive difference in the life of its patients. Every action counts!

To finance the Myeloma Canada Chair, the HMR Foundation raised some 2 million dollars from generous donors, including a contribution of $250,000 from the Foundation directly.

To learn more:

Hôpital Maisonneuve-Rosemont

Affiliated with Université de Montréal, Hôpital Maisonneuve-Rosemont is a major institution bringing together care, teaching, and medical research. Its 5,500 employees and physicians work with the population of Greater Montreal and beyond since the hospital has a supra-regional role. The HMR includes a world-class research centre. Three areas distinguish it nationally and internationally: vision health, hematology-oncology, and nephrology.  Each year, it receives more than 4,000 students, future doctors, nurses, and health professionals.

Within the context of the research of the Myeloma Canada Chair, the HMR provides infrastructure and access to specialized resources.

To learn more:


Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. Celgene Inc., a wholly-owned subsidiary of Celgene Corp., established its presence in Canada in 2006 and is located in Mississauga, Ontario.

Its mission is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions. There are more than 300 clinical trials at major medical centers using compounds from Celgene.  Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma.

To learn more:

Janssen Inc.

Janssen Inc., a pharmaceutical company of Johnson & Johnson, has been an innovator in the Canadian healthcare industry for over 50 years. It is guided by its credo, where the company’s first responsibility is to the doctors, nurses and patients, and mothers and fathers, and all others who use its products and services. Its ultimate goal is to help people live healthy lives.

To learn more: